Galmed Pharmaceuticals (NASDAQ:GLMD) (NASDAQ:GLMD) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for metabolic and liver diseases. The company’s lead product candidate, Aramchol® (arachidyl amido cholanoic acid), is a proprietary fatty acid–bile acid conjugate designed to target nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH). Galmed’s research aims to address key metabolic pathways implicated in liver fat accumulation and inflammation.
Aramchol is currently being evaluated in late-stage clinical trials, with a focus on demonstrating its potential to reduce liver fat content, improve markers of liver inflammation, and halt or reverse fibrotic progression. Preclinical studies have shown that Aramchol modulates both lipid metabolism and fibrogenesis, making it a dual-action candidate in the NASH treatment landscape. The company’s pipeline also includes earlier-stage assets targeting other metabolic diseases, leveraging its platform technology for lipid modulation.
Galmed Pharmaceuticals maintains strategic partnerships and licensing agreements to expand the global reach of Aramchol. The company has granted regional rights to various pharmaceutical partners for development and commercialization in markets such as Europe, Canada, and select Asian countries. Headquartered in Tel Aviv, Israel, Galmed operates R&D facilities there and engages with clinical research organizations across North America and Europe to conduct its pivotal trials.
Founded in 2000, Galmed has been led by an experienced management team with deep expertise in biotechnology and drug development. The company’s Executive Chairman, Dr. Yair Schwarz, co-founded Galmed and has guided its strategic direction, while William Mahoney, Chief Financial Officer, oversees financial planning and regulatory affairs. Together with a board of directors comprising industry veterans, Galmed seeks to advance its clinical programs and position Aramchol as a novel therapeutic option for patients suffering from NASH and related metabolic disorders.
